Background: ReCET utilizing an endoscope administered non-thermal pulsed electric field to stimulate duodenal cellular regeneration may correct abnormal duodenal signaling in type 2 diabetes (T2D). We report updated results from a feasibility study of ReCET therapy in T2D.

Method: This multicenter, open-label, treatment-only study recruited 18-70 yr old; T2D ≤10 years; HbA1c 7.5%-11.0%; BMI 24 - 40 kg/m2; C-peptide ≥ 333 pmol/l; and on 1-4 non-insulin glucose-lowering medications (GLMs) which were unchanged post-procedure. Primary endpoint: Device/procedure-related serious adverse events (SAEs). Secondary endpoints: Changes in metabolic parameters at 24W.

Results: Participants received single energy application (Single Tx, n=12), double energy application (Double Tx, n=18), or the Gen 2 catheter (Gen 2, n=21)- (Figure 1). Procedure success was 100% with no related SAEs. Common AEs were sore throat (25/51) and transient diarrhea (11/51), and mostly (76%) mild. Glycemia improved post procedure with trends suggesting an energy-dose response (Figure 1). Mean (SD) HbA1c at 24 wks vs baseline was 7.2 (1.2%) vs. 8.8 (0.9)% (p<0.01) in the Gen 2 group. Gen 2 group follow up is ongoing. Durability of glycemic improvement was observed in Double Tx group at 48 wks.

Conclusions: ReCET therapy is feasible and safe. Glycemic observations support further research.

graphic
View largeDownload slide
Disclosure

D.N. O'Neal: None. A. Sartoretto: Research Support; Endogenex, Erbe Electromedizin GmbH. Advisory Panel; Bariatek. Consultant; Boston Scientific Corporation, Intuitive Surgical. E.I. Ekinci: Advisory Panel; Lilly Diabetes. Research Support; Novo Nordisk, Boehringer-Ingelheim, Eli Lilly and Company. Board Member; Eli Lilly and Company. Advisory Panel; Abbott. Research Support; Endogenex, Versanis, AstraZeneca. G. Manos: None. B. Holt: None. G. Cameron: None. S. Chandran: None. R. Vaughan: None. B.K. Abu Dayyeh: Research Support; USGI Medical, Apollo Endosurgery. Consultant; Boston Scientific Corporation, Medtronic. Other Relationship; Endogenex. Research Support; ERBE.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.